Imatinib

Estrogen Receptor Positive

M.D. Anderson Cancer CenterSmall moleculePhase 2Dormant

B

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 42/ 100
Competitive Position: 89/ 100

Competitive context

77 Active assets in the Estrogen Receptor Positive cohort.

Asset / Sponsor	Phase	Rating
TAMOXIFEN Dana-Farber Cancer Institute	Phase 4	BBB
EXEMESTANE National Cancer Institute (NCI)	Phase 4	BBB
Everolimus UNC Lineberger Comprehensive Cancer Center	Phase 4	BBB
TAMOXIFEN Dana-Farber Cancer Institute	Phase 4	BB
Abemaciclib Jonsson Comprehensive Cancer Center	Phase 3	BB

View all 50 →

Same molecule, other indications

Imatinib is also rated in:

chronic myeloid leukemiaDormant

BB

Indicative ·

71 / 100

blast phase chronic myelogenous leukemia, BCR-ABL1 positiveDormant

BB

Indicative ·

71 / 100

B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant

BB

Indicative ·

69 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.